Applications of CRISPR Knock-in Tagging for Studying Endogenous Protein Dynamics
Discover Glo Webinar Series
Series Summary:
Over the last 30 years, assays and technologies utilizing the natural phenomenon of bioluminescence have gone from novel research tools to foundational elements of the modern research toolbox. Innovation utilizing bioluminescent approaches continues, further expanding both the available methods and the scientific advancements made by life science and drug discovery researchers. In this webinar series you will hear from industry experts and Promega scientists who will share research updates on important research topics included Kinases, GPCRs, and Targeted Protein Degradation. You will also learn about recent technology advancements that can be applied to these as well as other drug targets and research areas.
Session 2 - Applications of CRISPR Knock-in Tagging for Studying Endogenous Protein Dynamics
Summary
Advances in CRISPR/Cas9 gene editing have created new possibilities for studying both natural cellular biology and its modulation by potential therapeutic approaches. By using CRISPR/Cas9 gene editing to knock in bioluminescent reporter tags at endogenous loci, proteins are expressed by the native promoter and in their natural cellular context and can be studied using simple light output measurements. In this session, the scientists will describe how they have incorporated CRISPR/Cas9 gene editing and knock-in tagging into their research to perform functional analysis of endogenous proteins, gaining new insights into GPCR and PD-L1 biology. You will learn more about the method of performing endogenous tagging as well as new insights into these important drug targets.
Other webinars in this series:
Bioluminescence: Past, Present, Future
Speakers
Professor Kevin Pfleger, PhD
Director, Biomedical Innovation
University of Western Australia and MTPConnect WA Life Sciences Innovation Hub
Dr. Takahide, Matsushima
Assistant Professor
Tokyo Medical and Dental University
Dr. Takahide Matsushima received his PhD in Life Science at Hokkaido University. Since 2012 he has been an Assistant Professor at Tokyo Medical and Dental University in the department of Systems BioMedicine, where his research has focused on uncovering cellular mechanisms and pathways that directly affect cell proliferation and cancer development. A specific area of focus has been on the development and implementation of novel cellular assays that can be performed in high-throughput screening formats in order to identify novel compounds for potential cancer therapeutics.
Dr. Christopher Eggers
Senior Research Scientist
Promega Corporation
Dr. Christopher Eggers received his Ph.D. in biochemistry and molecular biology from the University of California at San Francisco and then completed a postdoctoral fellowship at the Howard Hughes Medical Institute at UC San Diego. Since 2011, Dr. Eggers has been a Senior Research Scientist at Promega, where he has focused principally on the development of the NanoLuc® and NanoBiT® technologies to create new bioluminescent assays that simplify the measurement of protein dynamics.